Stockscreener 앱 받기
31.48
0.05%
-0.015
전일 마감가:
$31.50
열려 있는:
$31.49
하루 거래량:
282.37K
Relative Volume:
0.13
시가총액:
$3.85B
수익:
$596.96M
순이익/손실:
$221.32M
주가수익비율:
18.10
EPS:
1.7397
순현금흐름:
$208.13M
1주 성능:
+0.17%
1개월 성능:
+0.68%
6개월 성능:
+38.57%
1년 성능:
+50.28%
1일 변동 폭
$31.48
$31.50
1주일 범위
$31.43
$31.50
52주 변동 폭
$19.05
$32.56
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
31.48 | 3.85B | 596.96M | 221.32M | 208.13M | 1.7397 |
VRTX
Vertex Pharmaceuticals Inc
|
524.24 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.56 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
921.42 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.37 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.67 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn - Investing.com
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data - TradingView
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Deep Value Play with Rare Disease Pipeline Strength - ChartMill
CPRXCatalyst Pharmaceuticals Inc Earnings - Finviz
Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE® - Yahoo Finance
Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression - Stock Titan
Catalyst reports Phase 1 vamorolone study results - Investing.com
Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses - The Manila Times
Catalyst's rare-disease steroid showed immune activity without the usual suppression - Stock Titan
Monolithic Power Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Monolithic Power Systems, Inc.MPWR - Business Wire
Skeletal Nickel Catalyst Market Growth to Accelerate by 2035 Amid Rising Pharma DemandNews and Statistics - IndexBox
Acadia Pharmaceuticals (ACAD) Gets 90-Day Catalyst Watch from Ci - GuruFocus
Quantified Common Ground Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In - Sahm
Shuttle Pharmaceuticals (NASDAQ:SHPH) surges; Dogecoin miner news sends volume up 70x - TechStock²
Price to earnings forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Price to sales forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Price to book forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Enterprise value to EBIT forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Enterprise value to EBITDA forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView
Understanding the Setup: (CPRX) and Scalable Risk - Stock Traders Daily
Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Nationwide Renaissance Small Cap Growth Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals stock edges higher to 31.41 after patient summit event, CatalystForRare - Traders Union
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - Business Wire
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes "Caviar Cruise" Quality Screen with Zero Debt and 147.5% ROIC - ChartMill
Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger - Sahm
Catalyst Pharmaceuticals to Be Acquired by Angelini Pharma in All-Cash Merger – Key Details from 8-K Filing - Minichart
Catalyst Pharma Gains FTC Clearance for Angelini Merger - TipRanks
Catalyst Pharmaceuticals merger cleared HSR waiting period as closing targets Q3 2026 - TradingView
HSR waiting period ends for Catalyst (NASDAQ: CPRX) and Angelini Pharma merger - Stock Titan
Catalyst Pharmaceuticals consensus steadies, Hold rating frames CPRX shares - AD HOC NEWS
Catalyst Pharmaceuticals Inc (CPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Catalyst Pharmaceuticals Inc - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SMID Core Equity Portfolio's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus
Catalyst Pharmaceuticals Inc (CPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Institutional Confidence - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Catalyst Pharmaceuticals Inc (CPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
The Technical Signals Behind (CPRX) That Institutions Follow - Stock Traders Daily
Angelini Pharma to buy Catalyst in deal worth $4.1 billion - MSN
HC Wainwright & Co. Downgrades Catalyst Pharmaceuticals (CPRX) - MSN
Catalyst Investor Sues Over Proposed $4.1B Angelini Buyout - Law360
Catalyst (CPRX) up 0.6% since last earnings report: Can it continue? - MSN
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Angelini Pharma to buy Catalyst (CPRX) for $31.50 per share; virtual vote July 8 - Stock Titan
Catalyst Pharmaceuticals | DEFM14A: Definitive proxy statement relating to merger or acquisition - Moomoo
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Catalyst Pharmaceuticals Inc 주식 (CPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Harper Molly | Director |
Dec 12 '25 |
Sale |
23.25 |
26,746 |
621,920 |
2,360 |
2.18%
2.70%
자본화:
|
볼륨(24시간):